Slowing Atherothrombosis Progression through Indoor Air Filtration: A Crossover Trial in Hispanic and non-Hispanic Adults with Ischemic Heart Disease History

通过室内空气过滤减缓动脉粥样硬化血栓形成的进展：对有缺血性心脏病史的西班牙裔和非西班牙裔成年人进行的交叉试验

• 批准号: 10688095
• 负责人: Zhanghua Chen
• 金额: $ 65.66万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688095
• 关键词: Acceleration; Acute; Adult; Adverse effects; Age; Aging; Air; Air Pollution; Area; Atherosclerosis; Biological Markers; Blood Glucose; Blood Pressure; Blood coagulation; C-reactive protein; Calendar; Calibration; California; Cardiometabolic Disease; Cardiovascular Diseases; Cause of Death; Censuses; China; Clinical; Computerized Medical Record; Cross-Over Studies; Cross-Over Trials; Crossover Design; Data; Devices; Diabetes Mellitus; Double-Blind Method; Elderly; Enrollment; Environmental Risk Factor; Ethnic Origin; Event; Exposure to; Female; Filtration; Future; Goals; Health; Heart failure; Hispanic; Hispanic Populations; Home visitation; In Vitro; Incidence; Individual; Inflammatory; Interleukin-6; International; Intervention; Intervention Trial; Life; Life Style; Link; Los Angeles; Measures; Methods; Minority Groups; Monitor; Morbidity - disease rate; Multicenter Trials; Myocardial Infarction; Myocardial Ischemia; Not Hispanic or Latino; Older Population; Outcome; P-Selectin; Participant; Particulate; Patients; Persons; Physiologic pulse; Plasma; Pollution; Population Heterogeneity; Populations at Risk; Predisposition; Process; Proteomics; Questionnaires; Randomized; Recording of previous events; Research Design; Research Personnel; Risk; Risk Factors; Sampling; Specific qualifier value; Statistical Data Interpretation; Stroke; Subgroup; Sudden Death; Teenagers; Thrombosis; Time; United States; United States National Institutes of Health; Universities; University resources; Variant; Vulnerable Populations; Wildfire; Woman; air cleaner; air filtration; air monitoring; arterial stiffness; atherothrombosis; burden of illness; cardiovascular disorder risk; cardiovascular risk factor; cost; design; efficacy evaluation; efficacy testing; epidemiology study; ethnic diversity; experience; feasibility trial; fine particles; high efficiency particulate air filter; improved; in vivo; indexing; indoor air; indoor particulate matter; interest; male; men; meteorological data; mortality; non-smoker; novel; pollutant; portability; prevent; primary outcome; residence; response; secondary outcome; sex; systemic inflammatory response; treatment arm; trial comparing; von Willebrand Factor

ABSTRACT Cardiovascular disease (CVD) is the leading cause of death in the US. There has been an increasing recognition of the important contribution of fine particulate pollution (PM2.5) to CVD morbidity and mortality. Mounting evidence suggests that the use of indoor air filtration to reduce PM2.5 exposure from days to weeks leads to improvement in acute atherothrombosis biomarkers. However, no trials have assessed whether these short-term effects are sustained or further improved with prolonged filtration. The proposed study is the longest intervention trial investigating the effect of using low-cost air purifiers in residences on ameliorating atherothrombosis progressions in vulnerable individuals. The study will examine atherothrombosis responses to HEPA filtration across and within four subgroups of male or female and Hispanic or non-Hispanic participants. We will leverage the diverse population in Los Angeles to investigate the effect of indoor PM2.5 filtration on both levels and slopes of change in atherothrombosis biomarkers including arterial stiffness, blood pressure, targeted proinflammatory and prothrombotic markers, and novel proteomic makers, as well as CVD risk score. The focus on the slopes of change over time is novel and will provide better prediction of future CVD events and mortality than biomarker level changes assessed in previous studies. We have an experienced team of investigators at the University of Southern California (USC) and Duke University and will leverage the rich patient resource from the USC KECK electronic medical records and the linked census-track PM2.5 data to enroll 100 participants of 65-84 years old non-smokers with a history of ischemic heart disease (clinically stable for at least 6 months) who have lived in the census track with higher ambient PM2.5 exposure in the past years. Participants will be block- randomized to two intervention arms (HEPA or sham filtrations, each of 9-month duration) and crossed over to the other intervention arm after a 3-month washout period. This design allows us to conduct the two intervention arms in the same calendar months of two consecutive years. Three home visits will be conducted during each intervention arm to set-up and calibrate air monitors, measure health outcomes, and collect biospecimens. Lifestyle and health covariates will be collected through online questionnaires. The crossover design and timing- controlled interventions will reduce the influence of confounding factors since participants serve as their own controls in the within-person comparison. Indoor and outdoor PM2.5 and co-pollutants will be measured; and meteorological data as well as wildfire events will be recorded throughout the trial. These covariates will be adjusted for in the statistical analyses. Our aims match the goal of NOT-HL-20-788 calling feasibility trials to investigate the effects of portable air cleaners on reducing PM2.5 exposure and CVD biomarkers including novel omics markers. Findings of the proposed study will provide the efficacy and feasibility data to support future nationwide or multi-center trials to further investigate the air filtration effect on adverse CVD event incidence and mortality.

摘要